Table 2.
Demographic/baseline characteristics | Total population N=679 | BBFC N=218 | Brinzolamide N=229 | Brimonidine N=232 |
---|---|---|---|---|
Age, years | ||||
Mean±standard deviation | 64.9±10.4 | 65.7±10.3 | 64.2±10.3 | 64.9±10.5 |
<65, n (%) | 323 (47.6%) | 98 (45.0%) | 110 (48.0%) | 115 (49.6%) |
≥65, n (%) | 356 (52.4%) | 120 (55.0%) | 119 (52.0%) | 117 (50.4%) |
Race, n (%) | ||||
White | 529 (77.9%) | 174 (79.8%) | 179 (78.2%) | 176 (75.9%) |
Black | 130 (19.1%) | 36 (16.5%) | 42 (18.3%) | 52 (22.4%) |
Asian | 9 (1.3%) | 3 (1.4%) | 5 (2.2%) | 1 (0.4%) |
Multi-racial | 3 (0.4%) | 0 (0%) | 1 (0.4%) | 2 (0.9%) |
Other | 8 (1.2%) | 5 (2.3%) | 2 (0.9%) | 1 (0.4%) |
Sex, n (%) | ||||
Male | 298 (43.9%) | 100 (45.9%) | 97 (42.4%) | 101 (43.5%) |
Female | 381 (56.1%) | 118 (54.1%) | 132 (57.6%) | 131 (56.5%) |
Diagnosis, n (%) | ||||
Ocular hypertension | 168 (24.7%) | 51 (23.4%) | 59 (25.8%) | 58 (25.0%) |
Open-angle glaucoma | 511 (75.3%) | 167 (76.6%) | 170 (74.2%) | 174 (75.0%) |
Demographics and baseline characteristics were presented from the intent-to-treat population.
Intraocular pressure was analyzed using the intent-to-treat population.
BBFC, brinzolamide 1%/brimonidine 0.2% fixed combination.